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Abstract
Background: More detailed understanding of herpes zoster (HZ) is called for in the context of an increasing observed
frequency of disease, and ongoing discussions regarding potential consequences of the disease. Thus, population-based
data on incidence and complications of HZ are needed.
Methods: We conducted a register-based cohort study in Västra Götaland County (population 1.5 million) in Sweden.
We collected data on all patients diagnosed with HZ during the years 2008 to 2010 from population-based registers.
Incidence rates (IR) of HZ and related complications were calculated and stratified by age and sex.
Results: There were 13 269 new HZ cases during the study period. Overall, the IR of herpes zoster in both genders was
3.25 (95 % CI: 3.16–3.34) per 1000 person years in 2010. The incidence was consistently higher in women than in men
and in older than in young. A history of immunosuppression was more common than in the general population. The
incidence was highest in individuals over 80 years of age (IR 9.2 per 1000 person years, 95 % CI: 8.8–9.6) during
2008–2010. The most common complications to HZ were ocular engagement and postherpetic neuralgia; risks for
stroke and sepsis were significantly elevated during the one year following diagnosis, especially in the youngest age
group of patients 0–39 years.
Conclusions: Herpes zoster is more common in women, the elderly and immunosuppressed individuals. We verify a
population-based association between herpes zoster and risk for stroke and sepsis, which may merit concern.
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Background
Herpes zoster, also called shingles, is a spontaneous
reactivation of a latent infection with varicella zoster
virus (VZV). Primary infection with VZV causes chicken-
pox, a common and typically benign exanthematous
childhood rash, after which VZV becomes latent in nerve
ganglia. The lifetime risk of re-activation is about 20–30 %
[1, 2]. Re-activation of VZV usually manifests as herpes
zoster with pain, rash, and vesicles in the area of skin
supplied by the affected nerve (dermatome). The risk
increases with age, as host cell-mediated immunity
declines, and herpes zoster is similarly also more
common in immunosuppressed patients. The most
common complication related to herpes zoster, espe-
cially among the elderly, is the pain syndrome post-
herpetic neuralgia (PHN), typically defined as pain
persisting more than 90 days [3], which can cause
severe distress. Other complications of herpes zoster
include bacterial skin infection, encephalitis, meningi-
tis, keratitis and herpes zoster ophtalmicus, the latter
of which has been associated with a risk of develop-
ing stroke [4, 5]. A possible biological explanation for
this association is the viral ability to replicate in cerebral ar-
teries where the infection is spread along the nerve fibers
to the blood vessels and thrombotic responses are induced
[6]. Regarding bacterial involvement after VZV infection,
this has been observed as a risk factor for invasive disease
and long-term complications [7].
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VZV vaccination is not part of the child vaccination
program in Sweden and VZV is therefore a common in-
fection in children. Over 90 % of the Swedish population
will have had chickenpox before 12 years of age, which
is more common than in southern Europe [8] and corre-
sponds to about a birth cohort every year (~100 000/
year in Sweden). With a viral reactivation of 20–30 %,
an extensive number of individuals are likely to be
affected each year in the population, although not every-
one will seek healthcare. Thus, estimation of real-life
incidence can be challenging, although such information
is increasingly needed as the introduction of VZV-
vaccination has taken place or is being contemplated in
a number of countries [9]. Therefore, in this study we
investigated herpes zoster incidence, complications, as-
sociated events, and the economic burden incurred;
using population-based health care registers in Sweden.
METHODS
Study population
We conducted a cohort study using population-based
health care registers in Västra Götaland County (VGC)
in Sweden. VGC is the second largest county in Sweden
and covers a stable population of approximately 1.5 mil-
lion inhabitants. Our study cohort consisted of all inci-
dent cases of herpes zoster in this region during years
2008 to 2010. The VGC Primary Health Care Register
(PHCR) includes records for all visits to general practi-
tioners in the county since 2000. The Swedish Patient
Register (SPR) records all in- and outpatient care visits
to hospitals and is complete in this aspect since 2001.
These two registers were used to find all registered inci-
dent cases of herpes zoster (ICD-10: B02) occurring in
the VGC population during the study years. The SPR
was also used to identify complications related to herpes
zoster, as this register holds more detailed information
on such compared to the PHCR, and to identify poten-
tial associated outcomes after herpes zoster as well as
underlying immunosuppressive conditions. Using the
Swedish personal identification number, which is unique
to each individual, we linked our cohort of herpes zoster
patients to other registers held at the Swedish National
Board of Health and Welfare. The National Cancer
Registry was used to identify patients with a cancer
diagnosis prior to herpes zoster, and the Swedish
Prescribed Drug Register (PDR) was used to collect
dispensation information on drugs associated with
treatment for herpes zoster, and immunosuppressive
drugs (see below).
Definitions of cases and complications
An incident case of herpes zoster was defined as receipt
of a diagnosis of herpes zoster (ICD-10: B02) during
2008–2010 in an individual with no diagnosis of herpes
zoster during the preceding year. PHN was defined as
having a combination of either ICD-10 code B02.2 and
G53.3, or B02 and G63.0 (either one of these as main/
secondary diagnosis) on the same date of diagnosis.
Other herpes zoster-related complications were defined
as receipt of a combination of ICD-10 code B02 diagno-
sis together with the ICD-10 code for the respective
complication/-s (Additional file 1: Table S1). A poten-
tially associated adverse event of either cardiovascular
disease (CVD excluding stroke), stroke, sepsis or Bell’s
palsy was defined as receipt of a diagnosis of such, ac-
cording to the respective ICD-10 code (Additional file 1:
Table S1) within one year following herpes zoster diag-
nosis. Immunosuppressed patients were defined as inci-
dent herpes zoster cases that had received either a
prescription of an immunosuppressive drug (Additional
file 1: Table S2) within 90–365 days prior to diagnosis of
herpes zoster, or a diagnosis of one of the following
immunosuppressive conditions (IC): HIV/AIDS, organ
transplantation, or any type of cancer (ICD10 C00-C99),
within one or five years prior to diagnosis (Additional
file 1: Table S1).
Case validation
To investigate the validity of a recorded diagnosis of
herpes zoster in the VGC PHCR and the SPR, we
performed a nested validation study. A random sample
of 112 cases was selected for the validation set. For these
patients, requests for copies of medical charts were sent
to the diagnosing clinic. All records were de-identified at
the clinic before review.
A clinician (KS) then reviewed all charts according to
a set of pre-defined criteria, to determine whether each
case of herpes zoster could be considered as a verified
case or not (Additional file 1: Table S3).
Statistical analyses
Incidence rates (IRs) and 95 % confidence intervals (CI)
of herpes zoster per 1,000 person-years were calculated
as the ratio of the number of incident cases to the total
amount of person-time at risk in the county. The rates
were both stratified by age at diagnosis (0–49/50–54/…
75–79/80+) as well as age-standardized to the Swedish
population in 2010, and further stratified by calendar
year of diagnosis and sex. IRs for herpes zoster-related
complications were calculated in a similar manner as for
herpes zoster, but expressed per 100,000 person-years.
The PHCR only uses the ICD-10 code B02, regardless of
whether the individual presents with any herpes zoster-
related complications. As the ICD-10 for PHN (G53) was
not available in this register, to study pain complications
we used a combination of appropriate ICD-10 codes with
complementary information from the PDR on analgesics
against neuropathic pain. We calculated the frequency
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and proportion of herpes zoster patients with a PHN
diagnosis, and/or a prescription for analgesics against
neuropathic pain, at the time of herpes zoster diagno-
sis, or within specified following time windows. We
considered both inclusive windows up to 90 days (≤30,
≤60, ≤90 days) as well as exclusive windows up to
1 year after diagnosis (0–30, 30–60, 60–90, 90–180,
and 180–365 days).
To quantify the association between herpes zoster and
potentially related adverse events such as stroke, patients
were followed for 1 year after diagnosis of herpes zoster,
within which all main diagnoses of the selected diseases
were recorded, as well as all person-time at risk. Patients
continued to be at risk for the full year, irrespective of
whether an adverse event occurred. Poisson regression
models were used to compare patients with herpes
zoster to the general population in VGC by estimating
incidence rate ratios (IRRs) with 95 % CIs. All models
were adjusted for sex and age, and in a second step the
effect was allowed to vary by sex and age by the inclu-
sion of interaction terms in the model.
Cost calculations
Overall costs for herpes zoster health care visits dur-
ing 2010 for Västra Götaland County were estimated.
Calculations included all health care visits with ICD-
code B02 as the main diagnosis and, using costing data
from the PDR, also all antiviral, ocular and specific
analgesic drugs purchased during 2010 within 90 days
after receiving a main diagnosis of herpes zoster. In
order to enable this 90-day follow up for all patients, 3992
individuals diagnosed between January-September of 2010
were included in these calculations. These individuals
were not required to be incident cases only; prevalent
cases were also included. Direct costs related to herpes
zoster were calculated from unit costs using regional
county council prices: 940 SEK per primary health care
visit, 2082 SEK per outpatient visit and 6313 SEK per day
for inpatient care. 1 Euro was calculated as equivalent to
9.43 SEK.
The study was approved by the Ethical Review Board
of Stockholm, which determined that informed consent
from the participants was not required.
Results
Case validation
A total of 73 % of the randomly sampled herpes
zoster cases could be directly verified through chart
review (81/112) as having ≥3 out of 5 pre-specified
symptoms (Additional file 1: Table S3). An additional
fifteen cases (13 %) were given a status of probable
herpes zoster diagnosis in the validation. These cases
were mainly difficult to verify due to only short notes
such as “typical herpes zoster”. Thus, the verification
proportion was 86 %. Thirteen cases (12 %) were
found to have an unclear/unlikely diagnosis of herpes
zoster, frequently due to the diagnosing clinician
having recorded uncertainty about the correct diagno-
sis, or an atypical symptom. Only 3 cases (3 %) were
found to have a clearly incorrect diagnosis.
Incidence of herpes zoster
In total, 13 296 incident cases of herpes zoster were
recorded in Västra Götaland County during the years
2008–2010 (Table 1). The number of new cases in-
creased per year (Additional file 1: Table S4), against
a background population that remained stable in size
(Additional file 1: Table S5). The overall incidence of
herpes zoster was 2.6 (95 % CI: 2.5–2.7) in 2008, 2.8
(95 % CI: 2.7–2.9) in 2009 and 3.3 (95 % CI: 3.2–3.3)
cases per 1000 person years in 2010 (Table 2). The
incidence was consistently higher in women than in
men. Gradually increasing with age, the incidence was
highest in those over 80 years (Fig. 1 and Table 2).
Pain related to herpes zoster
The proportion of all cases who received analgesics
against neuropathic pain within 90 days from diagnosis
was 5.5–6.7 % during 2008–2010. No substantial gender
differences in prescription patterns were discernible
(Table 3). In each time window, an additional 0.5–1
percentage unit of all remaining cases were also issued
such analgesics (Fig. 2). In terms of explicit diagnosis of
PHN, in applicable cases this was most commonly done
in conjunction with the herpes zoster diagnosis—i.e.
within 0–30 days—and was then a relatively rare event in
the following year (Fig. 2). Ultimately, 8.8 % of all men
and 9.5 % of all women with herpes zoster had received
analgesics and/or a diagnosis of PHN, at 1 year after diag-
nosis (2010 data, not shown). This proportion varied from
4 % in the age group 0–49 years, to 14.5 % in the oldest
age group above 80 years (2010 data, not shown).
Table 1 Age- and sex distribution of herpes zoster cases in
Västra Götaland County during year 2008–2010
Men Women Both sexes
Age N % N % N %
2008–2010 0–49 1,656 31.1 1,979 24.8 3,635 27.3
50–54 277 5.2 545 6.8 822 6.2
55–59 391 7.3 662 8.3 1,053 7.9
60–64 560 10.5 819 10.3 1,379 10.4
65–69 631 11.8 818 10.3 1,449 10.9
70–74 571 10.7 838 10.5 1,409 10.6
75–79 503 9.4 769 9.7 1,272 9.6
80+ 739 13.9 1,538 19.3 2,277 17.1
5,328 100 7,968 100 13,296 100
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Herpes zoster-related complications
The most commonly registered complications were
ocular engagement and PHN, representing a total of
4 % and 2 % of all cases, respectively, over the years
2008–2010. Severe complications such as dissemi-
nated herpes zoster (0.32 %), zoster-related encephal-
itis (0.29 %) and zoster-related meningitis (0.14 %)
were rare (Table 4). The incidence of complications
in 2010 was 11.5/100 000 person-years for ocular
engagement, 0.6/100 000 person-years for zoster-related
encephalitis and meningitis, and 1.2/100 000 person-years
for disseminated disease (data not shown). The incidence
of ocular engagement appeared higher in women than in
men but the rarity of severe complications precluded
Table 2 Incidence rates (IR) per 1,000 person-years of herpes zoster by sex, age and year
Men Women Both sexes
Age N IR (95 % CI) N IR (95 % CI) N IR (95 % CI)
2008–2010 0–49 1,656 1.1 (1.0–1.1) 1,979 1.4 (1.3–1.4) 3,635 1.2 (1.2–1.3)
50–54 277 1.9 (1.7–2.1) 545 3.7 (3.4–4.1) 822 2.8 (2.6–3.0)
55–59 391 2.7 (2.4–3.0) 662 4.6 (4.2–4.9) 1,053 3.6 (3.4–3.9)
60–64 560 3.7 (3.4–4.0) 819 5.4 (5.1–5.8) 1,379 4.5 (4.3–4.8)
65–69 631 5.3 (4.9–5.7) 818 6.8 (6.3–7.2) 1,449 6.0 (5.7–6.3)
70–74 571 6.6 (6.0–7.1) 838 8.8 (8.2–9.4) 1,409 7.7 (7.3–8.1)
75–79 503 7.4 (6.8–8.1) 769 9.1 (8.4–9.7) 1,272 8.3 (7.9–8.8)
80+ 739 8.0 (7.4–8.6) 1,538 9.9 (9.4–10.4) 2,277 9.2 (8.8–9.6)
2008 Total 1,595 2.1a (2.0–2.2) 2,319 3.0a (2.9–3.2) 3,914 2.6a (2.5–2.7)
0–49 449 0.9 (0.8–1.0) 530 1.1 (1.0–1.2) 979 1.0 (0.9–1.1)
50–54 81 1.6 (1.3–2.0) 161 3.3 (2.8–3.9) 242 2.5 (2.2–2.8)
55–59 131 2.7 (2.2–3.2) 180 3.7 (3.2–4.3) 311 3.2 (2.8–3.5)
60–64 168 3.3 (2.8–3.8) 223 4.4 (3.9–5.1) 391 3.9 (3.5–4.3)
65–69 178 4.8 (4.1–5.5) 240 6.3 (5.5–7.1) 418 5.5 (5.0–6.1)
70–74 183 6.6 (5.6–7.6) 263 8.5 (7.5–9.5) 446 7.6 (6.9–8.3)
75–79 185 8.1 (7.0–9.4) 251 8.8 (7.7–10.0) 436 8.5 (7.7–9.3)
80+ 220 7.2 (6.3–8.2) 471 9.1 (8.3–9.9) 691 8.4 (7.8–9.0)
2009 Total 1,719 2.2a (2.1–2.4) 2,606 3.4a (3.2–3.5) 4,325 2.8a (2.7–2.9)
0–49 538 1.1 (1.0–1.2) 628 1.3 (1.2–1.4) 1,166 1.2 (1.1–1.2)
50–54 89 1.8 (1.4–2.2) 182 3.7 (3.2–4.3) 271 2.8 (2.4–3.1)
55–59 109 2.3 (1.9–2.7) 226 4.7 (4.1–5.3) 335 3.5 (3.1–3.9)
60–64 190 3.7 (3.2–4.3) 268 5.3 (4.7–6.0) 458 4.5 (4.1–4.9)
65–69 209 5.3 (4.6–6.0) 281 7.0 (6.2–7.9) 490 6.1 (5.6–6.7)
70–74 179 6.2 (5.3–7.1) 252 7.9 (7.0–9.0) 431 7.1 (6.4–7.8)
75–79 158 7.0 (5.9–8.2) 245 8.7 (7.6–9.8) 403 7.9 (7.2–8.7)
80+ 247 8.0 (7.0–9.1) 524 10.1 (9.3–11.0) 771 9.3 (8.7–10.0)
2010 Total 2,014 2.6a (2.5–2.7) 3,043 3.9a (3.8–4.0) 5,057 3.3a (3.2–3.3)
0–49 669 1.3 (1.2–1.4) 821 1.7 (1.6–1.8) 1,490 1.5 (1.4–1.6)
50–54 107 2.1 (1.8–2.6) 202 4.1 (3.6–4.8) 309 3.1 (2.8–3.5)
55–59 151 3.2 (2.7–3.7) 256 5.4 (4.7–6.1) 407 4.3 (3.9–4.7)
60–64 202 4.0 (3.4–4.6) 328 6.5 (5.8–7.3) 530 5.2 (4.8–5.7)
65–69 244 5.7 (5.0–6.5) 297 7.0 (6.2–7.8) 541 6.4 (5.8–6.9)
70–74 209 7.0 (6.1–8.0) 323 9.9 (8.9–11.0) 532 8.5 (7.8–9.3)
75–79 160 7.1 (6.0–8.3) 273 9.8 (8.6–11.0) 433 8.6 (7.8–9.4)
80+ 272 8.8 (7.7–9.9) 543 10.5 (9.6–11.4) 815 9.8 (9.2–10.5)
aAge-standardized to the Swedish population 2010. Rates represent herpes zoster in Västra Götaland County, defined as all recorded cases of B02 ICD-10 codes as
main or secondary diagnosis
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meaningful interpretation of differences between sexes, or
age groups (data not shown).
Potentially associated events after herpes zoster
A total of 212 cases of CVD, stroke and sepsis occurred
within one year of herpes zoster diagnosis, in the cohort of
herpes zoster cases. The most frequent of these (n = 111)
was stroke. Compared to the general population, the
age- and sex-adjusted IRRs for CVD, stroke and sep-
sis were all significantly elevated (Table 5). When
allowing the effect to vary between sexes, men had a
significantly higher relative incidence of Bell’s palsy
(p < 0.01). There were no such differences in CVD,
stroke or sepsis. However, the IRRs for stroke and
sepsis differed by age group (p < 0.01), with 10-fold
increased IRRs in younger ages, whereas the IRRs in
older ages were close to unity (Table 5).
Immunosuppression and herpes zoster
During the study period, 819 of all cases (6.2 %) had
a prescription for an immunosuppressive drug within
90 days before diagnosis of herpes zoster. This
proportion increased with age: from 5.2 % in those
0–49 years to 12.6 % in those above 80 years (data
not shown). Depending on age group, 8.9 %–18.4 %
had had a prescription of immunosuppressive medication
within the preceding year, compared to only 5.2–15.1 % of
the general population in the same five-year age
groups from 0–49 to 80+. Furthermore, within the
preceding year, 3.2 % of all male cases and 2.2 % of all
female cases of herpes zoster had received a diagnosis
of an immunosuppressive condition. When consider-
ing the previous five years, these proportions in-
creased to 8.2 % and 6.8 %, respectively. The majority
of these derived from a previous diagnosis of any
cancer (data not shown).
Costs and health care utilization related to herpes zoster
The costs in year 2010 for VGC inpatient hospital stays,
outpatient visits and primary health care visits, incurred
by herpes zoster as a main diagnosis, amounted to
approximately 1.05 million Euro. More than half of the
cost (0.55 million Euro) was incurred in primary health
care, closely followed by inpatient care (0.42 million
Euro) whereas outpatient care had the lowest related
cost (0.08 million Euro). The total cost to VGC and its
patients for the above described herpes zoster-related
drug prescriptions was 0.28 million Euro. Patients with
complicated herpes zoster had relatively higher use of
in- and outpatient services than those with uncompli-
cated disease. They also had higher use of drugs; most
apparent for analgesics against neuropathic pain, which
was prescribed to only 1 in 5 of uncomplicated cases,
but in 1 of 2 complicated cases of herpes zoster, on
average (data not shown).
Discussion
We investigated the burden of herpes zoster disease
in a population-based register study of one of the
largest counties in Sweden between the years 2008
and 2010. The overall incidence for herpes zoster was
2.6–3.3 cases per 1000 person-years, ranging from
1.2–9.2 cases per 1000 person-years, depending on
age group. The healthcare costs in 2010 directly
related to the diagnosis amounted to at least 1.33
million Euro for the county of Västra Götaland, where
17 % of the nation’s inhabitants live. In accordance
with other studies, we observed an increase in herpes
zoster incidence over the years of study [10–12],
which in some countries has been attributed to the
introduction of vaccination against VZV. As the inci-
dence of chickenpox decreases in vaccinating coun-
tries, the elderly will not be exposed to a natural
booster by their grandchildren, which may increase
later herpes zoster incidence in older birth cohorts.
This theory could not, however, explain our findings,
since VZV vaccination is not part of the child vaccin-
ation program in Sweden. Our observed increase
could therefore at least in part be explained by other
factors, such as improved surveillance and reporting
of cases to health authorities. An ageing population
and an increasing number of immunosuppressed pa-
tients as a result of solid organ or bone marrow trans-
plantation, may also serve to explain this increasing
trend, which should be further investigated.
Herpes zoster incidence was generally higher in
women than in men, as observed previously [10, 13] and
in line with another Swedish study, although the use in
that study of prescription proxies, and hospitalization
data only, entails that comparison of incidence rates is
challenging [14]. Whether this gender difference is due
Fig. 1 Incidence of herpes zoster per 100 000 person-years in Västra
Götaland County during year 2008–2010, by age and calendar year
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Table 3 Frequency and proportion of herpes zoster cases with prescription of analgesics and/or PHN diagnosis
2008 2009 2010
Total number of HZ cases 3,914 Total number of HZ cases 4,325 Total number of HZ cases 5,057
n (%) n (%) n (%)
30 days 60 days 90 days 30 days 60 days 90 days 30 days 60 days 90 days
Prescriptiona
All 190 (4.9) 242 (6.2) 261 (6.7) 205 (4.7) 258 (6.0) 275 (6.4) 195 (3.9) 525 (5.0) 278 (5.5)
Sex
Male 65 (4.1) 89 (5.6) 96 (6.0) 85 (4.9) 107 (6.2) 114 (6.6) 83 (4.1) 103 (5.1) 113 (5.6)
Female 125 (5.4) 153 (6.6) 165 (7.1) 120 (4.6) 151 (5.8) 161 (6.2) 112 (3.7) 149 (4.9) 165 (5.4)
Age
0–49 19 (1.9) 21 (2.2) 22 (2.3) 16 (1.4) 21 (1.8) 26 (2.2) 18 (1.2) 27 (1.8) 29 (2.0)
50–54 5 (2.1) 8 (3.3) 10 (4.1) 11 (4.1) 13 (4.8) 13 (4.8) 7 (2.3) 10 (3.2) 13 (4.2)
55–59 14 (4.5) 14 (4.5) 14 (4.5) 16 (4.8) 24 (7.2) 24 (7.2) 14 (3.4) 17 (4.2) 18 (4.4)
60–64 12 (3.1) 13 (3.3) 15 (3.8) 19 (4.2) 22 (4.8) 22 (4.8) 21 (4.0) 23 (4.3) 24 (4.5)
65–69 22 (5.3) 28 (6.7) 30 (7.2) 25 (5.1) 33 (6.7) 34 (6.9) 24 (4.4) 33 (6.1) 36 (6.7)
70–74 23 (5.2) 28 (6.3) 31 (7.0) 22 (5.1) 27 (6.3) 30 (7.0) 34 (6.4) 43 (8.1) 47 (8.8)
75–79 34 (7.8) 45 (10.3) 47 (10.8) 32 (7.9) 38 (9.4) 39 (9.7) 29 (6.7) 36 (8.3) 37 (8.6)
80+ 61 (8.8) 85 (12.3) 92 (13.3) 64 (8.3) 80 (10.4) 87 (11.3) 48 (5.9) 63 (7.7) 74 (9.1)
PHN diagnosisb
All 58 (1.5) 68 (1.7) 73 (1.9) 58 (1.3) 66 (1.5) 70 (1.6) 55 (1.1) 66 (1.3) 69 (1.4)
Sex
Male 21 (1.3) 24 (1.5) 26 (1.6) 32 (1.9) 36 (2.1) 38 (2.2) 21 (1.0) 25 (1.2) 27 (1.3)
Female 37 (1.6) 44 (1.9) 47 (2.0) 26 (1.0) 30 (1.2) 32 (1.2) 34 (1.1) 41 (1.4) 42 (1.4)
Age
0–49 6 (0.6) 7 (0.7) 7 (0.7) 13 (1.1) 14 (1.2) 14 (1.2) 12 (0.8) 13 (0.9) 13 (0.9)
50–54 1 (0.4) 2 (0.8) 2 (0.8) 3 (1.1) 4 (1.5) 4 (1.5) 3 (1.0) 3 (1.0) 3 (1.0)
55–59 4 (1.3) 5 (1.6) 5 (1.6) 6 (1.8) 6 (1.8) 7 (2.1) 2 (0.5) 2 (0.5) 2 (0.5)
60–64 2 (0.5) 3 (0.8) 3 (0.8) 2 (0.4) 3 (0.7) 3 (0.7) 6 (1.1) 7 (1.3) 8 (1.5)
65–69 5 (1.2) 6 (1.4) 6 (1.4) 3 (0.6) 4 (0.8) 4 (0.8) 5 (0.9) 6 (1.1) 6 (1.1)
70–74 3 (0.7) 5 (1.1) 6 (1.4) 5 (1.2) 5 (1.2) 6 (1.4) 2 (0.4) 4 (0.8) 5 (0.9)
75–79 8 (1.8) 9 (2.1) 12 (2.8) 4 (1.0) 7 (1.7) 7 (1.7) 7 (1.6) 9 (2.1) 10 (2.3)
80+ 29 (4.2) 31 (4.5) 32 (4.6) 22 (2.9) 23 (3.0) 25 (3.2) 18 (2.2) 22 (2.7) 22 (2.7)
Prescriptiona and/or diagnosisb
All 240 (6.1) 294 (7.5) 313 (8.0) 251 (5.8) 305 (7.1) 322 (7.5) 240 (4.8) 298 (5.9) 325 (6.4)
Sex
Male 81 (5.1) 105 (6.6) 113 (7.1) 112 (6.5) 134 (7.8) 140 (8.1) 100 (5.0) 122 (6.1) 134 (6.7)
Female 159 (6.9) 189 (8.2) 200 (8.6) 139 (5.3) 171 (6.6) 182 (7.0) 140 (4.6) 176 (5.8) 191 (6.3)
Age
0–49 25 (2.6) 28 (2.9) 29 (3.0) 27 (2.3) 33 (2.8) 38 (3.3) 29 (2.0) 37 (2.5) 39 (2.6)
50–54 6 (2.5) 10 (4.1) 12 (5.0) 13 (4.8) 16 (5.9) 16 (5.9) 10 (3.2) 13 (4.2) 16 (5.2)
55–59 18 (5.8) 19 (6.1) 19 (6.1) 22 (6.6) 28 (8.4) 28 (8.4) 16 (3.9) 19 (4.7) 20 (4.9)
60–64 14 (3.6) 15 (3.8) 17 (4.4) 21 (4.6) 24 (5.2) 24 (5.2) 26 (4.9) 28 (5.3) 30 (5.7)
65–69 27 (6.5) 33 (7.9) 35 (8.4) 26 (5.3) 35 (7.1) 36 (7.4) 25 (4.6) 34 (6.3) 37 (6.8)
70–74 26 (5.8) 31 (7.0) 34 (7.6) 25 (5.8) 30 (7.0) 33 (7.7) 36 (6.8) 45 (8.5) 49 (9.2)
75–79 41 (9.4) 53 (12.2) 55 (12.6) 35 (8.7) 42 (10.4) 43 (10.7) 33 (7.6) 40 (9.2) 42 (9.7)
80+ 83 (12.0) 105 (15.2) 112 (16.2) 82 (10.6) 97 (12.6) 104 (13.5) 65 (8.0) 82 (10.1) 92 (11.3)
N (%) = Frequency (proportion) among total number of herpes zoster patients who had a prescription/diagnosis. aAccording to ATC codes in Additional file 1:
Table S2 bAccording to diagnosis codes in Additional file 1: Table S1
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to biological mechanisms and/or detection bias is not
known.
Although strongly related to increasing age, we further
observed that 30 % of our cases were found in patients
below 50 years of age, emphasizing the important
distinction that herpes zoster is not only a geriatric
affliction [10, 13, 15, 16].
The most frequent complications to herpes zoster were
pain, Bell’s palsy and ocular problems. Herpes zoster-
related meningitis and encephalitis were very rare, with an
incidence of less than 1/100 000 person-years. In a study
investigating viral DNA/RNA in cerebrospinal fluid from
patients with suspected infection and neurological
syndromes in Västra Götaland County, the estimated
incidence of VZV central nervous system infections
was 1.8/100 000 person-years [17], as defined by
positive PCR-detection of VZV DNA. Our findings as
recorded in the Swedish Patient Register may there-
fore represent a slight underestimation, likely due to
meningitis and encephalitis sometimes being coded as
“other meningitis and encephalitis”, without reference
to the correct B02 ICD code.
When studying the relation between immunosup-
pressive conditions (IC) and herpes zoster, we found
that 5–13 % of our cases had a prescription of an
immunosuppressive drug within 90 days before herpes
zoster diagnosis, and 6.8–8.2 % had a previous diagno-
sis of an IC condition, both of which findings confirm
results from a UK study where 8 % of hospitalized
herpes zoster cases had underlying IC [18]. The latter
observation also mirrors the findings by others on a
substantially increased risk of herpes zoster in those
Fig. 2 Proportion of cases with prescription of analgesics against neuropathic pain, or diagnosis of PHN
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with cancer and other immunosuppressive diagnoses
[16, 19]. We furthermore found that the preceding use
of immunosuppressive drugs was more common in our
herpes zoster patients than in the general population,
even in the ages below 50 years.
It has been proposed that the broader use of corticoids
in children is associated with more common affliction of
shingles in the same age group [20]. If this applies also
to adults, our findings may lend support to this argu-
ment, although it is possible that this association is
related instead to a higher relative use of healthcare
visits/resources.
The proportion of pain-related complications within
one year after diagnosis was up to 15 % in the oldest
population. The incidence of long-term post-herpetic
neuralgia (PHN) caused by herpes zoster varies between
studies depending on study population and definitions
used. Pain up to 30 days after diagnosis may reflect only
acute pain, and not true PHN [21]. We thus present data
per time window since diagnosis, to enable a distinction
between acute and long-term pain. We partially defined
pain/PHN through prescription proxies, and it is not
certain whether these analgesics against neuropathic
pain were prescribed specifically for pain related to her-
pes zoster; or actually for some other neuropathic condi-
tion. Nevertheless, we focused on reasonable time spans
for prescription, and analgesics in line with Swedish
guidelines for herpes zoster [22]. Indeed, our observa-
tions are in accordance with previous findings, where
the condition develops in 8–14 % of patients [23–25].
Herpes zoster may also be related to more severe
subsequent outcomes such as stroke [26], where one
potential mechanism could be direct infection of cere-
bral arteries [27]. We observed an increased risk of both
stroke and CVD within a year after herpes zoster, which
may be in line with previous reports of VZV-related
neurological sequelae [5, 17]. We also found that the
youngest population (0–39 years) had a 4-fold higher
risk of developing stroke within a year after herpes
zoster diagnosis—which may support previous findings
of VZV as a risk factor for stroke in children [28–30].
In one study, post-varicella cerebral infarctions in chil-
dren age 0–6 years were uniformly located to the middle
cerebral artery territory [29] and it may be of relevance
to investigate in clinical studies whether stroke after
herpes zoster might show a similar regional pattern.
Furthermore, bacteremia has been associated with
chickenpox/primary VZV infection in children [31, 32].
We observed an overall increased risk for subsequent
Table 4 Frequency and proportion of herpes zoster cases with
a related complication
Men Women Both sexes
N (%) N (%) N (%)
Herpes zoster (HZ) 5,328 (100) 7,968 (100) 13,296 (100)
HZ + PHN 121 (2.27) 157 (1.97) 278 (2.09)
HZ + ocular 218 (4.09) 325 (4.08) 543 (4.08)
HZ + encephalitis 13 (0.24) 26 (0.33) 39 (0.29)
HZ +meningitis 11 (0.21) 8 (0.10) 19 (0.14)
Disseminated HZ 19 (0.36) 24 (0.30) 43 (0.32)
Other HZ complications 69 (1.30) 89 (1.12) 158 (1.19)
HZ without complications 1,127 (21.2) 1,613 (20.2) 2,740 (20.6)
Table 5 Incidence rate ratios (IRR) for associated outcomes within a year following herpes zoster diagnosis
CVD (excl. stroke) Stroke Sepsis Bell’s palsy
n IRRa (95 % CI) n IRRa (95 % CI) n IRRa (95 % CI) n IRRa (95 % CI)
All cases 64 1.82 (1.42–2.33) 111 1.34 (1.12–1.62) 37 1.47 (1.06–2.03) 71 10.6 (8.33–13.4)
Sex
Men 26 1.62 (1.10–2.38) 49 1.30 (0.98–1.72) 15 1.23 (0.74–2.05) 43 15.7 (11.6–21.3)
Women 38 1.99 (1.45–2.74) 62 1.38 (1.08–1.77) 22 1.68 (1.11–2.56) 28 6.99 (4.80–10.2)
p-valueb 0.41 0.75 0.36 <0.01
Age (years)
0–39 0 . 4 10.3 (3.87–27.6) 3 9.10 (2.93–28.3) 15 23.4 (14.0–38.9)
40–49 1 1.15 (0.16–8.16) 0 . 3 9.42 (3.02–29.3) 1 2.62 (0.37–18.6)
50–59 12 3.51 (1.99–6.19) 2 0.44 (0.11–1.76) 0 . 6 7.23 (3.23–16.2)
60–69 21 2.68 (1.75–4.12) 13 1.12 (0.65–1.92) 3 0.79 (0.25–2.44) 17 9.09 (5.61–14.7)
70–79 16 1.37 (0.84–2.25) 35 1.47 (1.05–2.04) 6 0.79 (0.35–1.76) 13 7.69 (4.42–13.4)
80+ 14 1.29 (0.76–2.18) 57 1.38 (1.07–1.80) 22 1.82 (1.19–2.77) 19 14.4 (9.03–23.0)
p-valuec 0.06 <0.01 <0.01 0.01
aAdjusted for age and sex
bFrom Wald test of interaction between HZ and sex
cFrom Wald test of interaction between HZ and age group
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sepsis in herpes zoster patients and the largest risk
increase (9-fold) was again found in the youngest age
group, which may indicate that herpes zoster is a risk
factor in young individuals, similar to chickenpox. These
analyses do not adjust for potential confounders in terms
of co-morbidities and therefore should be interpreted
with caution. Nevertheless, even if there is no causal
relation, it is conceivable that occurrence of herpes
zoster could act as a risk marker for subsequent severe
disease in vulnerable populations.
Since this is a register-based study, there are some
instances where registration may have been imperfect,
and our conclusions affected, as described above. How-
ever, we conclude after our chart validation that our use
of the diagnosis code B02 is highly valid. If at least half
of the unclear cases were actually cases of sub-optimally
documented herpes zoster, the verification proportion
would be around 86 %, a figure reflected in other studies
[33]. Our proportion of false positives therefore appears
low, and although we did not assess the proportion of
false negatives, our observed incidence is in line with the
published literature, which should entail that our ap-
proach is valid for the proportion of herpes zoster cases
which have merited/triggered health care attention.
Regarding costs, we did not consider costs for
complications that were not connected to the ICD-
code B02; prescriptions >90 days after herpes zoster
diagnosis, or additional treatments for IC patients
with herpes zoster. Also, our definition of IC was
somewhat limited compared to other studies. Other
studies who have considered these and other add-
itional factors observe a higher cost related to herpes
zoster treatment [34, 35]. Our estimates of costs
should therefore be regarded as conservative.
Conclusion
In summary, herpes zoster is a common disease afflict-
ing the population, particularly women, the elderly,
and the immunosuppressed. Consistent signs of po-
tentially severe associated events or complications,
now verified in a population-based setting, should
prompt further mechanistic studies and investigation
into high risk-groups.
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